# Clinical Trials Data EGFR - Document 22

# Combination of Chemotherapy and Gefitinib as First-line Treatment

## Clinical Trial: https://clinicaltrials.gov/study/NCT02148380

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Signed informed consent\n2. Age \\>=18 years\n3. Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic Stage IV Non-Small Cell Lung Cancer (NSCLC)\n4. A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology)\n5. Measurable or non-measurable disease\n6. Able to comply with study and follow-up procedures\n\nExclusion Criteria:\n\n\* Evidence of small cell, carcinoid, or mixed small cell/non-small cell histology\n\* Malignancies within 3 years except for adequately treated carcinoma in situ of -the cervix or basal or squamous cell skin cancer\n\* Symptomatic or untreated brain metastases\n\* Prior systemic chemotherapy for NSCLC\n\* Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or serious cardiac arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible)\n\* History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications\n\* Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, or prior surgical procedures affecting absorption\n\* Pregnancy or lactation",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial eligibility criteria, there is no mention of any exclusion or inclusion related specifically to EGFR gene mutations.   
  
Eligibility is based on factors like the type and stage of the disease (NSCLC, Stage IV), prior treatments (e.g., not having had prior systemic chemotherapy for NSCLC), and absence of certain conditions (e.g., no symptomatic brain metastases). Since the EGFR mutation is not addressed, it does not automatically exclude or include the patient from the trial.  
  
However, EGFR mutations can sometimes influence treatment outcomes and preferences in clinical trials targeting NSCLC. It would be advisable for the patient to consult with the clinical trial team or a medical professional to determine if any updates or additional criteria might be relevant to their involvement in the study.